Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00721955 · ClinicalTrials.gov registry record · Phase 3
Staccato Loxapine in Agitated Patients With Bipolar Disorder
A Phase 3 study, sponsored by Alexza Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 314
- Enrollment target
NCT00721955 is a Phase 3 study that has completed, run by Alexza Pharmaceuticals. The registered enrollment target is 314 participants.
The verdict
NCT00721955, a Phase 3 study, has completed, sponsored by Alexza Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 314 participants
- Enrollment target
Study Summary
Phase 3 safety and efficacy study of Staccato Loxapine in the treatment of acute agitation in bipolar 1 disorder patients.
Interventions
- DRUG Inhaled Placebo
- DRUG Inhaled loxapine 5 mg
- DRUG Inhaled loxapine 10 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 314 participants |
| Start Date | 2008-07 |
| Est. Completion | 2008-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00721955
The ClinicalTrials.gov registry entry for NCT00721955 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 314 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexza Pharmaceuticals, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Inhaled Placebo is the first listed.
NCT00721955 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00721955 about?
NCT00721955 is a clinical study titled "Staccato Loxapine in Agitated Patients With Bipolar Disorder". Phase 3 safety and efficacy study of Staccato Loxapine in the treatment of acute agitation in bipolar 1 disorder patients.
What is the current status of trial NCT00721955?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 314 participants. The study started on 2008-07. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00721955?
The interventions under investigation include: Inhaled Placebo (DRUG), Inhaled loxapine 5 mg (DRUG), Inhaled loxapine 10 mg (DRUG).
Who is sponsoring clinical trial NCT00721955?
This trial is sponsored by Alexza Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.